Tuhina Neogi, MD
Rheumatology · Boston, MANPI 1912965179
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $162,249 of the $241,627 with a category attached, or 67.1%. 17 manufacturers reported payments, led by Pfizer at 45.6% of the total. Reporting peaked in 2020 at $57,428 and has fallen 85.3% since, to $8,465 in 2025. Among rheumatology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $2416.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$110K
- Eli Lilly$36K
- Regeneron$15K
- GSK$13K
- EMD Serono, Inc.$11K
- Novartis$11K
- plus $45K from 11 others
Across 36 payments — averaging $96,777 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.7M
- Novartis$1.6M
- EMD Serono, Inc.$101K
- Amgen$75K
- Regeneron$22K
What the payments were for
- Consulting fees$162,24967%
- Speaking & faculty fees$74,30531%
- Travel & lodging$4,0842%
- Food & beverage$8850%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $110,299 |
| Eli Lilly | 30 | $35,870 |
| Regeneron | 6 | $15,132 |
| GSK | 5 | $12,879 |
| EMD Serono, Inc. | 3 | $11,309 |
| Novartis | 6 | $11,195 |
| Merck | 9 | $8,465 |
| ANI Pharmaceuticals, Inc. | 8 | $7,837 |
| Teva Pharmaceuticals USA, Inc. | 1 | $6,413 |
| Alnylam Pharmaceuticals Inc. | 4 | $5,600 |
| Pacira Therapeutics, Inc. | 3 | $4,200 |
| Amgen | 6 | $3,452 |
| Sobi, Inc | 2 | $2,610 |
| Swedish Orphan Biovitrum AB | 1 | $2,500 |
| Sanofi | 1 | $2,376 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $840 |
| Novo Nordisk | 1 | $650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURIFIED CORTROPHIN GEL$7,692
- KRYSTEXXA$3,163
- Gamifant$2,500
- KEVZARA$2,376
- Non-Covered Product$840
- Sprifermin$600
- Synagis$110
How this compares
$241,627 in reported general payments places this provider in the 95th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 53 | $491,646 |
| Colchicine | 25 | $1,566 |
| MethotrexateMethotrexate Sodium | 38 | $1,295 |
| Diclofenac Sodium | 14 | $848 |
| Allopurinol | 27 | $341 |
| Hydroxychloroquine Sulfate | 12 | $272 |
| Prednisone | 18 | $226 |
| Pregabalin | 13 | $57 |
| Meloxicam | 14 | $50 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Boston
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Tanya LaidlawBoston$244K
- Michael WeinblattBoston$228K
- Michael BrennerBoston$115K
- Zachary WallaceBoston$106K
- Flavia CastelinoBoston$96K
- Joerg ErmannBoston$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.